Relaxing patent rights in a pandemic is a win for innovators and the public
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.